Fatty acids and obesity

Current Pharmaceutical Design

Volumn 15, Issue 36, 2009, Pages 4117-4125

  Bermudez Menendez De La Granda M ^a   Sinclair, A J ^b  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^b UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

Author keywords

Body composition; Conjugated linoleic acid; Obesity; Polyunsaturated fatty acids

Indexed keywords

ALPHA TOCOPHEROL; CONJUGATED LINOLEIC ACID; DOCOSAHEXAENOIC ACID; FATTY ACID; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; SIMVASTATIN;

BIOLOGICAL ACTIVITY; BODY COMPOSITION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIET THERAPY; DIETARY REFERENCE INTAKE; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; FAT INTAKE; FISH MEAT; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; NAUSEA; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION;

BODY COMPOSITION; DIET; DIETARY SUPPLEMENTS; FATTY ACIDS, UNSATURATED; FOOD ANALYSIS; HUMANS; OBESITY;

EID: 71849100087     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789909674     Document Type: Review

References (105)

1. World Health Organization. Global database on body mass index. http://apps.who.int/bmi/index.jsp retrieved on July 2009.
2. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Bodymass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341: 1097-1105 (Pubitemid 29466221)
3. Colditz GA, Willett WC, Stampfer MJ, Manson JE, Hennekens CH, Arky RA, et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 1990; 132: 501-513 (Pubitemid 20285148)
4. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990; 322: 882-889 (Pubitemid 20108377)
5. Alexander JK. Obesity and coronary heart disease. Am J Med Sci 2001; 321: 215-224
6. Reaven GM. The metabolic syndrome: Is this diagnosis necessary? Am J Clin Nutr 2006; 83: 1237-1247
7. Lee JH, O'Keefe JH, Lavie CJ, Marchioli R, Harris WS. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc 2008; 83: 324-332
8. Pariza MW. Perspective on the safety and effectiveness of conjugated linoleic acid. Am J Clin Nutr 2004; 79: 1132S-6S.
9. Hainault I, Carlotti M, Hajduch E, Guichard C, Lavau M. Fish oil in a high lard diet prevents obesity, hyperlipidemia, and adipocyte insulin resistance in rats. Ann N Y Acad Sci 1993; 683: 98-101. (Pubitemid 23236657)
10. Belzung F, Raclot T, Groscolas R. Fish oil n-3 fatty acids selectively limit the hypertrophy of abdominal fat depots in growing rats fed high-fat diets. Am J Physiol 1993; 264: R1111-8.
11. Ruzickova J, Rossmeisl M, Prazak T, Flachs P, Sponarova J, Veck M, et al. Omega-3 PUFA of marine origin limit diet-induced obesity in mice by reducing cellularity of adipose tissue. Lipids 2004; 39: 1177-1185
12. Buckley JD, Howe PR. Anti-obesity effects of long-chain omega-3 polyunsaturated fatty acids obesity reviews Anti-obesity effects of long-chain omega-3 polyunsaturated fatty acids. Obes Rev 2009; May 12. [Epub ahead of print]
13. He K, Rimm E, Merchant A, Rosner B, Stampfer M, Willett W, et al. Fish consumption and risk of stroke in men. JAMA 2002; 288: 3130-3136 (Pubitemid 36014130)
14. Iso H, Rexrode KM, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, et al. Intake of fish and omega-3 fatty acids and risk of stroke in women. JAMA 2001; 285: 304-312 (Pubitemid 32095033)
15. Kabir M, Skurnik G, Naour N, Pechtner V, Meugnier E, Rome S, et al. Treatment for 2 mo with n-3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am J Clin Nutr 2007; 86: 1670-1679 (Pubitemid 350232182)
16. Fontani G, Corradeschi F, Felici A, Alfatti F, Bugarini R, Fiaschi AI, et al. Blood profiles, body fat and mood state in healthy subjects on different diets supplemented with Omega-3 polyunsaturated fatty acids. Eur J Clin Invest 2005; 35: 499-507. (Pubitemid 41153204)
17. Thorsdottir I, Tomasson H, Gunnarsdottir I, Gisladottir E, Kiely M, Parra M. Randomized trial of weight-loss-diets for young adults varying in fish and fish oil content. Int J Obes 2007; 31: 1560-1566 (Pubitemid 47482660)
18. Warner J, Ullrich I, Albrink M, Yeater R. Combined effects of aerobic exercise and omega-3 fatty acids in hyperlipidemic persons. Med Sci Sports Exerc 1989; 21: 498-505. (Pubitemid 19260155)
19. Hill A, Buckley J, Murphy K, Howe P. Combining fish oil supplementation with regular aerobic exercise improves body composition and cardiovascular risk factors. Am J Clin Nutr 2007; 85: 1267-1274 (Pubitemid 46740468)
20. Bang HO, Dyerberg J. Plasma lipids and lipoproteins in Greenlandic west coast eskimos. Acta Med Scand 1972; 192: 85-94.
21. Kris-Etherton PM, Harris WS, Appel LJ, American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease [published correction appears in Circulation. 2003; 107: 512]. Circulation 2002; 106: 2747-2757
22. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: A meta-analysis of randomized controlled trials. Am J Med 2002; 112: 298-304. (Pubitemid 34219443)
23. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM.et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2: 757-761 (Pubitemid 19234807)
24. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354: 447-455
25. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105: 1897-1903
26. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis [published correction appears in Lancet. 2007; 370: 220]. Lancet 2007; 369: 1090-1098
27. Harris WS. Omega-3 fatty acids and cardiovascular disease: a case for omega-3 index as a new risk factor. Pharmacol Res 2007; 55: 217-223
28. Anand RG, Alkadri M, Lavie CJ, Milani RV. The role of fish oil in arrhythmia prevention. J Cardiopulm Rehabil Prev 2008; 28: 2-8.
29. O'Keefe JH Jr, Abuissa H, Sastre A, Steinhaus DM, Harris WS. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol 2006; 97: 1127-1130
30. Ventura HO, Milani RV, Lavie CJ, Smart FW, Stapleton DD, Toups TS, et al. Cyclosporine-induced hypertension: efficacy of omega-3 fatty acids in patients after cardiac transplantation. Circulation 1993; 88: II281-5.
31. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003; 361: 477-485
32. Din JN, Harding SA, Valerio CJ, Sarma J, Lyall K, Riemersma RA, et al. Dietary intervention with oil rich fish reduces platelet-monocyte aggregation in man. Atherosclerosis 2008; 197: 290-296
33. Abuissa A, O'Keefe JH Jr, Harris WS, Lavie CJ. Autonomic function, omega-3, and cardiovascular risk. Chest 2005; 127: 1088-1091
34. Mozaffarian D, Geelen A, Brouwer IA, Geleinjnse JM, Zock PL, Katan MB. Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation 2005; 112: 1945-1952
35. Christensen JH. n-3 fatty acids and the risk of sudden cardiac death. Emphasis on heart rate variability. Dan Med Bull 2003; 50: 347-367
36. Harris WS, Poston WC, Haddock CK. Tissue n-3 and n-6 fatty acids and risk for coronary heart disease events. Atherosclerosis 2007; 193: 1-10.
37. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997; 65: 1645s-54
38. Davidson MH, Stein EA, Bayes HE, Maki KC, Doyle RT, Shalwitz RA, et al. COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo controlled study. Clin Ther 2007; 29: 1354-1367
39. Harris WS, Ginsberg HN, Arunakul N, Shachter NS, Windsor SL, Adams M, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovas Risk 1997; 4: 385-391
40. Hartweg J, Perera R, Montori V, Dinneen S, Neil HAW, Farmer A. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; 1: CD003205.
41. Sommerfield T, Price J, Hiatt WR. Omega-3 fatty acids for intermittent claudication. Cochrane Database Syst Rev 2007; 4: CD003833.
42. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 1993; 88: 523-533 (Pubitemid 23228051)
43. Appel LJ, Miller III ER, Seidler AJ, Whelton PK. Does supplementation of diet with 'fish oil' reduce blood pressure? Arch Intern Med 1993; 153: 1429-1438
44. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 2002; 20: 1493-1499
45. Zhao G, Etherton TD, Martin KR, Gilles PJ, West SG, Kris-Etherton PM. Dietary alpha-linolenic acid inhibits proinflammatory cytokine production by peripheral blood mononuclear cells in hypercholesterolemic subjects. Am J Clin Nutr 2007; 85: 385-391 (Pubitemid 46220938)
46. Itoh M, Suganami T, Satoh N, Tanimoto-Koyama K, Yuan X, Tanaka M, et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol 2007; 27: 1918-1925 (Pubitemid 47315642)
47. Kratz M, Swarbrick M, Callahan H, Matthys CC, Havel PJ, Weigle DS. Effect of dietary n-3 polyinsaturated fatty acids on plasma total and high-molecular-weight adiponectin concentrations in overweight to moderately obese men and women. Am J Clin Nutr 2008; 87: 347-353 (Pubitemid 351226070)
48. Harris WS. Expert opinion: omega-3 fatty acids and bleeding - cause for concern? Am J Cardiol 2007; 99: 44C-6.
49. Mori TA, Woodman RJ. The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care 2006; 9: 95-104.
50. Ness AR, Hughes J, Elwood PC, Whitley E, Smith GD, Burr ML. The long-term effect of dietary advice in men with coronary disease: followup of the diet and reinfarction trial. Eur J Clin Nutr 2002; 56: 512-518 (Pubitemid 34649729)
51. Burr ML, Ashfield-Watt PAL, Dunstan FDJ, Fehily AM, Breay P, Ashton T, et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr 2003; 57: 193-200. (Pubitemid 36240469)
52. Ness AR, Ashfield-Watt PAL, Whiting JM, Smith GD, Hughes J, Burr ML. The long-term effect of dietary advice on the diet of men with angina: the diet and angina randomized trial. J Hum Nutr Diet 2004; 17: 117-119 (Pubitemid 38455721)
53. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Moore H, Worthington HV, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev 2004, 4: CD003177.
54. von Schacky C, Harris WS. Cardiovascular benefits of omega-3 fatty acids. Cardiovasc Res 2007; 73: 310-315 (Pubitemid 44937689)
55. Li JJ; Huang CJ; Xie D. Anti-obesity effects of conjugated linoleic acid, docosahexaenoic acid, and eicosapentaenoic acid. Mol Nutr Food Res 2008, 52: 631-645
56. Gaullier J-M, Berven G, Blankson H, Gudmundsen O. Clinical trials support a preference for using CLA preparations enriched with two isomers rather than four isomers in human studies. Lipids 2002; 37: 1019-1025 (Pubitemid 36120301)
57. Park Y, Albright KJ, Liu W, Storkson JM, Cook ME, Pariza MW. Effect of conjugated linoleic acid on body composition in mice. Lipids 1997; 32: 853-858 (Pubitemid 27360392)
58. West DB, Delany JP, Camet PM, Blohm F, Truett AA, Scimeca J. Effect of conjugated linoleic acid on body fat and energy metabolism in the mouse. Am J Physiol 1998; 275: R667-72.
59. Delany JP, Blohm F, Truett AA, Scimeca JA, West DB. Conjugated linoleic acid rapidly reduces body fat content in mice without affecting energy intake. Am J Physiol 1999; 276: R1172-9.
60. Terpstra AHM, Beynen AC, Everts H, Kocsis S, Katan MB, Zock PL. The decrease in body fat in mice fed conjugated linoleic acid is due to increases in energy expenditure and energy loss in the excreta. J Nutr 2002; 132: 940-945 (Pubitemid 34493557)
61. Gavino VC, Gavino G, Leblanc M-J, Tuchweber B. Anisomeric mixture of conjugated linoleic acids but not pure cis-9, trans-11-octadecadienoic acid affects body weight gain and plasma lipids in hamsters. J Nutr 2000; 130: 27-29 (Pubitemid 30032824)
62. Martin JC, Valeille K. Conjugated linoleic aids: all the same or to everyone its own function? Reprod Nutr Dev 2002; 42: 525-536
63. Clement L, Poirier H, Niot I, Bocher V, Guerre-Millo M, Krief S, et al. Dietary trans-10, cis-12 conjugated linoleic acid induces hyperinsulemia and fatty liver in the mouse. J Lipid Res 2002; 43: 1400-1409
64. Park Y, Storkson JM, Albright KJ, Liu W, Pariza MW. Evidence that the trans-10, cis-12 isomer of conjugated linoleic acid induces body composition changes in mice. Lipids 1999; 34: 235-241 (Pubitemid 29169626)
65. Pariza MW, Park Y, Cook ME. The biologically active isomers of conjugated linoleic acid. Prog Lipid Res 2001; 40: 283-298 (Pubitemid 32547235)
66. Ryder JW, Portocarrero CP, Song XM, Cui L, Yu M, Combatsiaris T, et al. Isomer-specific antidiabetic properties of conjugated linoleic acid. Improved glucose tolerance, skeletal muscle insulin action, and UCP-2 gene expression. Diabetes 2001; 50: 1149-1157
67. Roche HM, Noone E, Sewter C, Mc Bennett S, Savage D, Gibney MJ, et al. Isomer-dependent metabolic effects of conjugated linoleic acid. Insight from molecular markers sterol regulatory element binding protein-1c and LXRalpha. Diabetes 2002; 51: 2037-2044
68. Tsuboyama-Kasaoka N, Takahashi M, Tanemura K, Kim HJ, Tange T, Okuyama H, et al. Conjugated linoleic acid supplementation reduces adipose tissue by apoptosis and develops lipodystrophy in mice. Diabetes 2000; 49: 1534-1542 (Pubitemid 30677247)
69. Caldor PC. Conjugated linoleic acid in humans: reasons to be cheerful? Curr Opin Clin Nutr Metab Care 2002; 5: 123-126
70. Kelley DS, Erickson KL. Modulation of body composition and immune cell functions by conjugated linoleic acid in humans and animal models: benefits vs. risks. Lipids 2003; 38: 377-386
71. Terpstra AH. Effect of conjugated linoleic acid on body composition and plasma lipids in humans: an overview of the literature. Am J Clin Nutr 2004; 79: 352-361 (Pubitemid 41115576)
72. Blankson H, Stakkestad JA, Fagerton H, Thom E, Wadstein J, Gudmundsen O. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. J Nutr 2000; 130: 2943-2948 (Pubitemid 32005322)
73. Gaullier JM, Halse J, Hoye K, Kristiansen K, Fagertun H, Vik H, et al. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. Am J Clin Nutr 2004; 79: 1118-1125 (Pubitemid 41095966)
74. Mougios V, Matsakas A, Petridou A, Ring S, Sagredos A, Melissopoulou A, et al. Effect of supplementation with conjugated linoleic acid on human serum lipids and body fat. J Nutr Biochem 2001; 12: 585-594 (Pubitemid 32930054)
75. Smedman A, Vessby B. Conjugated linoleic acid supplementation in humans-metabolic effects. Lipids 2001; 36: 773-781 (Pubitemid 32924104)
76. Gaullier JM, Halse J, Høivik HO, Høye K, Syvertsen C, Nurminiemi M, et al. Six months supplementation with conjugated linoleic acid (CLA) induces regional-specific fat mass decreases in overweight and obese. Br J Nutr 2007; 97: 50-60.
77. Watras AC, Buchholz AC, Close RN, Zhang Z, Schoeller DA. The role of conjugated linoleic acid in reducing body fat and preventing holiday weight gain. Int J Obes 2007; 31: 481-487 (Pubitemid 46318618)
78. Pinkoski C, Chilibeck PD, Candow DG, Esliger D, Ewaschuk JB, Facci M, et al. The effects of conjugated linoleic acid supplementation during resistance training. Med Sci Sports Exerc 2006; 38: 339-348 (Pubitemid 43271588)
79. Berven G, Bye A, Hals O, Blankson H, Fagertun H, Thom E , et al. Safety of conjugated linoleic acid (CLA) in overweight or obese human volunteers. Eur J Lipid Sci Technol 2000; 102: 455-462
80. Riserus U, Arner P, Brismar K, Vessby B. Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome. Diabetes Care 2002; 25: 1516-1521 (Pubitemid 41071104)
81. Malpuech-Brugere C, Verboeket-van de Venne WP, Mensink RP, Arnal MA, Morio B, Brandolini M, et al. Effects of two conjugated linoleic acid isomers on body fat mass in overweight humans. Obes Res 2004; 12: 591-598
82. Atkinson RL. In: Yurawecz MP, Mossoba MM, Kramer JKG, Pariza MW, Nelson GJ. Eds, Advances in conjugated linoleic acid research. Vol 1. Champaign, IL: AOCS Press 1999; 348-353
83. Kreider RB, Ferreira MP, Greenwood M, Wilson M, Almada AL. Effects of conjugated linoleic acid supplementation during resistance training on body composition, bone density, strength, and selected hematological markers. J Strength Cond Res 2002; 16: 325-334
84. Riserus U, Vessby B, Arnlov J, Basu S. Effects of cis-9,trans-11 conjugated linoleic acid supplementation on insulin sensitivity, lipid peroxidation, and proinflammatory markers in obese men. Am J Clin Nutr 2004; 80: 279-283 (Pubitemid 41079999)
85. Petridou A, Mougios V, Sagredos A. Supplementation with CLA: isomer incorporation into serum lipids and effect on body fat of women. Lipids 2003; 38: 805-811 (Pubitemid 37193740)
86. Eyjolfson V, Spriet LL, Dyck DJ. Conjugated linoleic acid improves insulin sensitivity in young, sedentary humans. Med Sci Sports Exerc 2004; 36: 814-820 (Pubitemid 38596386)
87. Taylor JS, Williams SR, Rhys R, James P, Frenneaux MP. Conjugated linoleic acid impairs endothelial function. Arterioscler Thromb Vasc Biol 2006; 26: 307-312 (Pubitemid 43732192)
88. Lambert EV, Goedecke JH, Bluett K, Heggie K, Claassen A, Rae DE, et al. Conjugated linoleic acid (CLA) vs. high-oleic acid sunflower oil: effects on energy metabolism, glucose tolerance, blood lipids, appetite and body composition in regularly exercising individuals. Br J Nutr 2007; 97: 1001-1011 (Pubitemid 46554416)
89. Gaullier JM, Halse J, Høye K, Kristiansen K, Fagertun H, Vik H , et al. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans. J Nutr 2005; 135: 778-784 (Pubitemid 40464104)
90. Whigham L D, Watras A C, Schoeller D A. Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. Am J Clin Nutr 2007; 85: 1203-1211 (Pubitemid 46740460)
91. Kamphuis MM, Lejeune MP, Saris WH, Westerterp-Plantenga MS. The effect of conjugated linoleic acid supplementation after weight loss on body weight regain, body composition, and resting metabolic rate in overweight subjects. Int J Obes Relat Metab Disord 2003; 27: 840-847
92. Larsen TM, Toubro S, Gudmundsen O, Astrup A. Conjugated linoleic acid supplementation for 1 y does not prevent weight or body fat regain. Am J Clin Nutr 2006; 83: 606-612 (Pubitemid 44699206)
93. Whigham LD, O'Shea M, Mohede IC, Walaski HP, Atkinson RL. Safety profile of conjugated linoleic acid in a 12-month trial in obese humans. Food Chem Toxicol 2004; 42: 1701-1709 (Pubitemid 39078517)
94. Moloney F, Yeow TP, Mullen A, Nolan JJ, Roche HM. Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus. Am J Clin Nutr 2004; 80: 887-895 (Pubitemid 41202087)
95. Medina EA, Horn WF, Keim NL, Havel PJ, Benito P, Kelley DS, et al. Conjugated linoleic acid supplementation in humans: effects on circulating leptin concentrations and appetite. Lipids 2000; 35: 783-788 (Pubitemid 30624544)
96. Noone EJ, Roche HM, Nugent AP, Gibney MJ. The effect of dietary supplementation using isomeric blends of conjugated linoleic acid on lipid metabolism in healthy human subjects. Br J Nutr 2002; 88: 243-251
97. Belury MA. Dietary conjugated linoleic acid in health: physiological effects and mechanisms of action. Annu Rev Nutr 2002; 22: 505-531 (Pubitemid 35221471)
98. Belury MA, Mahon A, Banni S. The conjugated linoleic acid (CLA) isomer, t10c12-CLA, is inversely associated with changes in body weight and serum leptin in subjects with type 2 diabetes mellitus. J Nutr 2003; 133: 257S-60S.
99. Basu S, Riserus U, Turpeinen A, Vessby B. Conjugated linoleic acid induces lipid peroxidation in men with abdominal obesity. Clin Sci 2000; 99: 511-516 (Pubitemid 32014557)
100. Riserus U, Berglund L, Vessby B. Conjugated linoleic acid (CLA) reduced abdominal adipose tissue in obese middle-aged men with signs of the metabolic syndrome: a randomised controlled trial. Int J Obes Relat Metab Disord 2001; 25: 1129-1135
101. Albers R, van der Wielen RP, Brink EJ, Hendriks HF, Dorovska- Taran VN, Mohede IC. Effects of cis-9, trans-11 and trans-10, cis- 12 conjugated linoleic acid (CLA) isomers on immune function in healthy men. Eur J Clin Nutr 2003; 57: 595-603. (Pubitemid 36553600)
102. Song HJ, Grant I, Rotondo D, Mohede I, Sattar N, Heys SD, et al. Effect of CLA supplementation on immune function in young healthy volunteers. Eur J Clin Nutr 2005; 59: 508-517 (Pubitemid 40528664)
103. Banks WA. The blood-brain barrier as a cause of obesity. Curr Pharm Des 2008; 14(16): 1606-1614
104. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 2009; 15(13): 1546-1558
105. Goodman CD, McFadden GI. Fatty acid synthesis in protozoan parasites: unusual pathways and novel drug targets. Curr Pharm Des 2008; 14(9): 901-916